ClinicalTrials.gg
CompletedNCT00453271Updated May 23, 2013

Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail

A Phase 2 interventional study of NB-002 and Vehicle control in Onychomycosis, sponsored by NanoBio Corporation. Completed at 24 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-05-23.

Sponsored by NanoBio Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
443
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Onychomycosis with a site in United States — 3 open to participants now, 7 under way, 1 of them phase 3. Onychomycosis · United States.

Enrollment
12th of 75
443 · median 50
Started
2007
with 2 others
Phase 2
23 of 77
1 open now
Registered
7th of 77
by date

Among the 77 studies in Onychomycosis with a site in United States, this one is the 12th largest by enrollment of the 75 interventional ones that give a count, is one of 3 that started in 2007, is one of 23 in phase 2, and was the 7th registered.

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

Browse Onychomycosis studies →

Open to participants now

3 of the 77 studies in Onychomycosis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Onychomycosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to determine whether NB002, 0.25%, and 0.5% are safe and effective in the treatment of distal subungual onychomycosis of the toenail.

Read the detailed description

The purpose of the study is to determine whether NB002, 0.25%, and 0.5% are safe and effective in the treatment of distal subungual onychomycosis of the toenail.

03

Conditions studied

  • Onychomycosis

Browse trials for

Keywords

  • chronic persistent infection of the nail bed or plate
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • are healthy males or females between the ages of 18 and 75 years of age;
  • have a clinical diagnosis of mild to moderate DSO in the nail of at least one great toe, involving 25%-67% of the nail, without lunular or proximal involvement;
  • positive mycology results (ie, KOH test and culture of a dermatophyte) from the target great toenail;
  • refrain from using any lotions, creams, liquids, or polish on treated toenails or on the skin immediately adjacent to the toenails during the treatment period unless directed to do so by the investigator;
  • are willing to refrain from using topical or topical antifungals on toenails or the skin immediately adjacent to the toenails; or systemic antifungals for the duration of the study;

Exclusion criteria

Exclusion Criteria:

  • females who are pregnant, plan to become pregnant during the study, or are nursing a child;
  • are hypersensitive to topical creams, ointments, medications, or surfactants;
  • have received systemic antifungal therapy for any reason within 3 months, or topical antifungal therapy on the toenails or skin immediately adjacent to the toenails within 3 weeks prior to the start of the study; or
  • have taken any drug within 4 weeks prior to the start of the study.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
443 participants (actual)

Study arms

  • Experimental
    NB-002 0.25% BID

    Drug: NB-002

  • Experimental
    NB-002 0.5% QD

    Drug: NB-002

  • Experimental
    NB-002 0.5% BID

    Drug: NB-002

  • Sham comparator
    Vehicle control

    Drug: Vehicle control

Interventions

06

What researchers measure

Primary outcomes

  1. Planimetry assessment of the target great toenail

    Time frame: Week 24

  2. Rate of complete cure

    Time frame: Week 46

  3. Rate of therapeutic success

    Time frame: Week 46

Secondary outcomes

  1. Investigator's visual assessment of length of new unaffected nail

  2. The presence/absence of DSO on all toenails

07

Study locations

24 sites
  • International Dermatology Research
    Miami, Florida 33144, United States
  • Northwest Clinical Trial
    Boise, Idaho 83704, United States
  • Welborne Clinic
    Evansville, Indiana 47713, United States
  • Michigan Center for Research Corp.
    Clinton Township, Michigan 48038, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Academic Dermatology Associates
    Albuquerque, New Mexico 87106, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Oregon Medical Research Center, PC
    Portland, Oregon 97223, United States
  • DermResearch Inc.
    Austin, Texas 78759, United States
  • J & S Studies, Inc.
    Bryan, Texas 77802, United States
  • Endeavor Clinical Trials, PA
    San Antonio, Texas 78229, United States
  • Dermatology Research Center, Inc.
    Salt Lake City, Utah 84124, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23507, United States
  • Newlab Clinical Research, Inc.
    St. John's, Newfoundland and Labrador A1B 4S8, Canada
  • Eastern Canada Cutaneous Research Associates, LTD
    Halifax, Nova Scotia B3H 1A4, Canada
  • Ultranova Skincare
    Barrie, Ontario L4M 6L2, Canada
  • The Guenther Dermatology Research Centre
    London, Ontario N6A 3H7, Canada
  • Lynderm Research, Inc.
    Markham, Ontario L3P 1A8, Canada
  • Dermatology Clinic
    Mississauga, Ontario L4Y 1A6, Canada
  • EntraLogix Clinical Group, Inc.
    Oakville, Ontario L6K1E1, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Innovaderm Research, Inc.
    Montreal, Quebec H2K 4L5, Canada
  • International Dermatology Research, Inc.
    Montreal, Quebec H3H 1U4, Canada
  • Centre de Reeberche Dermatologique du Quebec Metropolitain (CRDQ)
    Quebec, G1V 4X7, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2007
First posted
Mar 28, 2007
Start
Jan 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results delay requested
May 15, 2013
Last update
May 23, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00453271
Lead sponsor
NanoBio Corporation
Responsible party
Sponsor
First posted
Mar 28, 2007
Start date
Jan 2007
Primary completion
Oct 2008
Completion
Oct 2008
Last update
May 23, 2013

Study contacts

Alicia Barba, MD
principal investigator · International Dermatology Research, Inc.
Alicia Bucko, DO
principal investigator · Academic Dermatology Associates
Richard Pollak, DPM, MS
principal investigator · Endeavor Clinical Trials, PA
Michael Jarratt, MD
principal investigator · Derm Research, PLLC
Terry Jones, MD
principal investigator · J & S Studies, Inc.
Robert Kaylor, DPM
principal investigator · Welborne Clinic
Steven Kempers, MD
principal investigator · Minnesota Clinical Study Center
Robert Matheson, MD
principal investigator · Oregon Medical Research Center, PC
Brock McConnehey,, DO
principal investigator · Northwest Clinical Trial
David Pariser, MD
principal investigator · Virginia Clinical Research, Inc.
Phoebe Rich, MD
principal investigator · Oregon Dermatology and Research Center
Dan Stewart, DO
principal investigator · Michigan Center for Research Corp
Leonard Swinyer, MD
principal investigator · Dermatology Research Center, Inc.
Robert Bissonette, MD
principal investigator · Innovaderm Research Inc.
Sylvia Garnis-Jones, MD
principal investigator · EntraLogix Clinical Group Inc.
David Gratton, MD
principal investigator · International Dermatology Research, Inc.
Lyn Guenther, MD
principal investigator · The Guenther Dermatology Research Centre
Rod Kunynetz, MD
principal investigator · Ultranova Skincare
Charles Lynde, MD
principal investigator · Lynderm Research, Inc.
Richard Langley, MD
principal investigator · Eastern Canada Cutaneous Research Associates, LTD
Kim Papp, MD
principal investigator · K. Papp Clinical Research
Yves Poulin, MD
principal investigator · Centre de Reeberche Dermatologique du Quebec Metropolitain (CRDQ)
Wayne Gulliver, MD
principal investigator · Newlab Clinical Research Inc.
R G Sibbald, MD
principal investigator · Dermatology Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetylpyridinium

Start the discussion